ResMed Inc. (RMD) Up 4.6% — Should I Build a Stake Now?
Key Points
ResMed Inc. (RMD) showed strong performance in the latest session, advancing 4.59% to close at $262.95, gaining $11.54 on the day from a prior finish of $251.41. The move reflects bullish activity, with the stock continuing to gain ground after recent trading around lower levels. Trading volume came in at 991,517 shares, slightly below its 90-day average of 1,044,529, indicating that the latest surge in price occurred without a spike in trading activity. Even with today’s solid advance, the stock remains below its 52-week peak of $293.81 set on Aug. 22, 2025, leaving additional upside potential of roughly $30.86, or just over 10%, before retesting that high-water mark.
ResMed’s latest upswing stands out among major Health Care peers such as Abbott Laboratories (ABT), Intuitive Surgical (ISRG), and Stryker (SYK). While individual daily moves vary across the group, RMD’s nearly 5% daily gain marks a notably stronger showing than is typical for large-cap Health Care names in a single session. The stock’s ability to push higher on only modestly lighter-than-average volume suggests steady buying interest rather than short-lived trading activity, reinforcing the impression of constructive momentum. With shares now trading closer to the upper end of their 52-week range but still shy of prior highs, the price action points to a stock that has been gaining ground and retaining a bullish tone within its industry.
Why ResMed Inc. Price is Moving Higher
ResMed Inc.’s recent price strength is being driven primarily by a strong Q2 fiscal 2026 earnings report that exceeded market expectations and reinforced a positive growth narrative. The company delivered non-GAAP EPS of $2.81, topping consensus estimates of $2.68, alongside 11% year-over-year revenue growth to $1.42 billion. Investors are also responding to improving profitability, with gross margin expanding 320 basis points to 61.8%, supported by scale benefits and operational efficiency. Robust operating cash flow of $340 million further underscores solid fundamentals and cash generation capacity. Against this backdrop, the company’s quarterly dividend declaration of $0.60 signals confidence in ongoing cash flow and adds an income component that can enhance total return potential for shareholders.
Momentum is being reinforced by favorable Street sentiment and institutional support. Citigroup raised its price target to $345 and reiterated a buy rating, citing post-earnings strength and growth visibility, while Royal Bank of Canada lifted its target to $314 with an outperform call. These higher targets contribute to a Moderate Buy consensus near $299, suggesting analysts see additional upside from current levels. At the same time, institutional interest remains constructive: Allianz Asset Management increased its stake by over 110,000 shares to hold roughly 0.24% of the company, a vote of confidence that tends to resonate with other market participants. A small planned insider sale of 50 shares appears immaterial against this backdrop. Within the broader Health Care Equipment and Services space, ResMed’s combination of double-digit revenue growth and a profit margin above 27% is helping fuel the bullish tone around the stock.
What is the ResMed Inc. Rating - Should I Buy?
Weiss Ratings assigns RMD a C rating. Current recommendation is Hold. Within the Health Care sector, this places ResMed Inc. in line with many established names, similar to Stryker Corporation (SYK, C), and ahead of UnitedHealth Group Incorporated (UNH, C-) on our scale. For investors, a C rating indicates an overall risk/reward profile that is about average, but ResMed’s underlying strengths may appeal to those looking for quality fundamentals in a long-term watchlist candidate.
The standout feature for RMD is its operational performance. The Excellent Growth Index is backed by double-digit revenue growth of 10.98%, while the Excellent Efficiency Index is supported by a robust 27.52% profit margin and a 25.68% return on equity. These measures indicate that ResMed is managing costs well and generating attractive returns on shareholder capital. The Excellent Solvency Index further signals a solid balance sheet, which is especially important in the capital-intensive health care space.
Where ResMed lags is in shareholder return metrics. The Total Return Index and Volatility Index are both Fair, meaning past price performance and risk-adjusted returns have been middle-of-the-pack rather than leadership-caliber. The Weak Dividend Index shows that income generation is a relative soft spot compared with peers like Abbott Laboratories (ABT, C+) and Intuitive Surgical, Inc. (ISRG, C+), which together help frame ResMed’s positioning within the sector.
Overall, the C (Hold) rating captures this mix: strong business quality and financial strength, offset by only moderate stock performance and limited dividend appeal.
About ResMed Inc.
ResMed Inc. is a global leader in medical devices and digital health solutions focused on the treatment of sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. Operating within the Health Care Equipment and Services industry, the company is best known for its comprehensive portfolio of sleep and respiratory care products, including continuous positive airway pressure (CPAP) devices, bilevel devices, ventilators, and a wide range of masks and accessories. These solutions are designed to help patients manage obstructive sleep apnea and other respiratory disorders in both home and clinical settings, supporting better adherence to therapy and improved quality of life.
Beyond its core devices, ResMed has built a significant presence in cloud-connected and software-driven care. Many of its devices incorporate wireless connectivity and integrate with digital platforms that allow clinicians and home medical equipment providers to monitor therapy, adjust settings remotely, and streamline workflow. The company also offers software-as-a-service (SaaS) solutions for out-of-hospital care, including tools for managing home health, hospice, and long-term care services. This combination of hardware and digital platforms positions ResMed as a key player in the shift toward more connected, value-based care models, where data-driven insights and remote monitoring can enhance patient outcomes and operational efficiency across the care continuum.
Investor Outlook
With a C (Hold) Weiss Rating, ResMed Inc. (RMD) appears positioned for potential incremental gains as it navigates evolving conditions in the Health Care space. Investors may want to watch how the stock behaves around recent trading ranges and monitor sector trends that could influence future rating changes or improved reward-to-risk dynamics. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--